NRAS

Innovate BC Awards $1.365M to B.C. R&D Projects Solving Real-World Challenges

Retrieved on: 
星期二, 九月 26, 2023
NRAS, Adhesive, Interim, University, Innovate BC, Clean, Aluminium, Electricity, Enzyme, Quality of life, Innovation, Research, Cell, Natural Resources, University of Victoria, Regeneration, Corrosion, Nature, Mining, Economic development, Simon Fraser University, Knowledge, Clean technology, Courage, Technology transfer, Renewable energy, 3D printing, Fine chemical, Management

VANCOUVER, B.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Last night at an awards ceremony in Vancouver, Innovate BC awarded $1.365M to five B.C.

Key Points: 
  • VANCOUVER, B.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Last night at an awards ceremony in Vancouver, Innovate BC awarded $1.365M to five B.C.
  • Specifically, this year’s funding, through Innovate BC’s Ignite program, is accelerating the commercialization of clean technology, advanced materials and manufacturing, and life science projects.
  • Awarded: $300,000
    “Innovate BC is honoured to support and invest in research and development projects in the natural resources and applied sciences,” says Tomica Divic, Interim President + CEO at Innovate BC.
  • Each year Innovate BC’s Ignite program selects research projects in the natural resources and applied sciences, awarding up to $300,000 per project.

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

Retrieved on: 
星期一, 九月 18, 2023
Perk, NRAS, Workforce, FGFR, DNA, Pancreatic cancer, DUSP6, PRS, Class II, Class, DCR, Clinical trial, DC, DL 2, Trae tha Truth, First grade, MEK inhibitor, BRAF, Research, Itch, MEK, RNA, Lung cancer, Completeness, Binimetinib, Rash, ORR, Vomiting, Investment, Patient, SAN, Melanoma, ERK, Weakness, Nausea, ALT, Neoplasm, CDK4, FDA, FGFR2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, SD, KNTE, Food, PR, Safety, Fatigue, RAF, Pharmaceutical industry, Cryptocurrency, Medical imaging, Vaccine

(Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.
  • Additionally, Kinnate will pause development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248, as part of the reprioritization plan.
  • We believe that reprioritizing our programs is the most effective approach to unlock the full promise of our innovative therapies.”
    Farzan added, “The reprioritization plan unfortunately impacts our workforce.
  • Kinnate will implement a corporate restructuring by reducing the Company’s workforce by approximately 70%.

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

Retrieved on: 
星期三, 八月 30, 2023
NRAS, Tissue, KRAS, National Human Genome Research Institute, TP53, Serum, Breast, Cancer, National Cancer Institute, Brain, Prostate, Lung, Colon, Plasma, The Cancer Genome Atlas, PTEN, EGFR, Risk, Melanoma, DTC, MET, TCGA, RET, ALK, Medical imaging

LEXINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the launch of a new program that gives researchers consistent and direct access to mutation-characterized formalin-fixed, paraffin-embedded (“FFPE”) cancer tumor tissues, relieving a major bottleneck in cancer research. The program will initially offer samples for lung, colon and breast cancers.

Key Points: 
  • The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics.
  • “This is a very important program for the future of iSpecimen.
  • Our new cancer sequencing procurement program provides cancer researchers with access to mutation-characterized FFPE tumor tissues without requiring that they manage the risk and resource-intense course of overseeing the sequencing process,” said Tracy Curley, iSpecimen’s CEO.
  • As this program progresses, pre-screened samples will be offered for a number of additional cancer types, including pancreatic, renal, brain, ovarian, gastric, melanoma, bladder and prostate.

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Retrieved on: 
星期二, 八月 29, 2023
NRAS, KRAS, POC, NSCLC, MEK, Novartis, Patient, SAN, Melanoma, Safety, Pharmaceutical industry, Medical imaging

SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient in the SEACRAFT-1 Phase 1b trial evaluating pan-RAF inhibitor naporafenib in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.

Key Points: 
  • “Naporafenib has been dosed in over 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept (PoC) in multiple indications,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder.
  • “SEACRAFT-1 will explore the potential of naporafenib plus trametinib in patients with RAS Q61X solid tumors, which affects over 150,000 patients in the United States and Europe.
  • This tissue agnostic approach is based on the encouraging anti-tumor activity generated by Novartis in patients with NRAS Q61X melanoma or KRAS Q61X non-small cell lung cancer (NSCLC).
  • In addition, we are on track to initiate SEACRAFT-2, a pivotal Phase 3 trial to evaluate naporafenib plus trametinib in patients with NRAS-mutant (NRASm) melanoma, in the first half of 2024.”

Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
星期二, 八月 8, 2023
NRAS, FGFR, Brain, Research, MEK, Lung cancer, Binimetinib, Investigational New Drug, American Chemical Society, Investment, SAN, Poster, Neoplasm, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, KNTE, Food, Pharmaceutical industry, Cryptocurrency, Video game

(Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the second quarter of 2023 and recent corporate updates.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the second quarter of 2023 and recent corporate updates.
  • Second quarter research and development expenses for 2023 were $26.3 million, compared to $19.8 million for the same period in 2022.
  • Second quarter general and administrative expenses for 2023 were $7.8 million, compared to $7.6 million for the same period in 2022.
  • Second quarter net loss for 2023 was $31.9 million, compared to $27.1 million for the same period in 2022.

KBRA Releases Research – CMBS Servicer Advance Trends: Curtailment and Recovery

Retrieved on: 
星期五, 八月 4, 2023
Banking, Professional Services, Insurance, Finance, KBRA, CMBS, Delinquent, NRAS, Aras, ARA, CRE, NRA, Research, Bank

KBRA releases research on the trends in commercial mortgage-backed securities (CMBS) servicer advances and their curtailment and recovery.

Key Points: 
  • KBRA releases research on the trends in commercial mortgage-backed securities (CMBS) servicer advances and their curtailment and recovery.
  • The specially serviced loan rate in KBRA-rated private-label U.S. CMBS continued to trend higher in June as it breached 6%, ending 1H 2023 at 6.07%.
  • Given the expected increase in servicer advances, KBRA has conducted a study on how these advances—along with ARAs, NRA determinations, and recoveries via WODRAs—have trended over the past year.
  • Conduits with the most in outstanding advances are generally from the 2013-15 vintages, as these generally have higher delinquency levels.

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期三, 八月 2, 2023
KRAS, Plantar fibromatosis, Marketing, Neoplasm, New Drug Application, Janssen, G&A, MEK, Cycle, Pain, Congress, Nirogacestat, RAS, Patient, Janssen Pharmaceuticals, Research and development, R, Prescription Drug User Fee Act, European Hematology Association, Multiple myeloma, MAPK, Decentralized finance, Research, GSK plc, PDUFA, Growth, Teclistamab, FDA, Common, RAF, NRAS, Solar cycle 10, GSK, AACR, CD3, Cancer, American Association for Cancer Research, BRAF, Solar cycle 2, TEAD, Administration, RRMM, Therapy, NDA, ASCO, American Society of Clinical Oncology, Annual general meeting, EHA, Mouse, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, BCMA, Pharmaceutical industry

STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2023 and provided an update on recent company developments.

Key Points: 
  • STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2023 and provided an update on recent company developments.
  • In May 2023, SpringWorks announced full enrollment of the Phase 2 trial evaluating nirogacestat as a monotherapy in patients with recurrent ovarian granulosa cell tumors.
  • SpringWorks expects to file an Investigational New Drug Application for SW-682 in the fourth quarter of 2023.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported net loss of $77.9 million, or $1.25 per share, for the second quarter of 2023.

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Retrieved on: 
星期二, 六月 20, 2023
Oncology, Medical Supplies, Health, Biometrics, Health Technology, Genetics, Biotechnology, ENDO, NRAS, Thyroid nodule, Database, DNA, Malignancy, Memorial Hermann Health System, Aggression, HRAS, Cancer, Lymph, Research, RNA, Washington University in St. Louis, Thyroid, FNA, Patient, Physician, Risk, TERT, Endocrine Society, Diagnosis, GSC, Metastasis, Biopsy, Medical device, Endocrinology

(Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.

Key Points: 
  • (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.
  • “These data demonstrate that our Afirma molecular testing capabilities and genomic-profile database are valuable tools that can help researchers better understand the genomic underpinnings of thyroid nodules and cancer,” said Joshua Klopper, M.D., Veracyte’s medical director of Endocrinology.
  • They assessed the signatures among known malignancies and indeterminate nodules (Bethesda III-IV) classified as suspicious for cancer by the Afirma Genomic Sequencing Classifier (GSC).
  • “Our study demonstrates that the Afirma testing platform and database can be used as a research tool to develop novel genomic research signatures that may help advance the understanding of thyroid cancer behavior,” said Dr. Golding.

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

Retrieved on: 
星期一, 六月 5, 2023
NRAS, AACR, PD, Half-life, HRAS, SRC, Cancer, American Association for Cancer Research, Mutation, Cmax, Optimus, Patient, Data, China Bio-Immunity Corporation, Toxic leukoencephalopathy, Caregiver, Safety, Pharmaceutical industry, Immune-related response criteria

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the completion of the dose-escalation portion of the Phase 1/2a study for its lead asset IMM-1-104 in patients with advanced solid tumors. The study’s Safety Review Committee (SRC) completed its evaluation and determined that doses up to and including 320 mg once daily are tolerable with no dose limiting toxicities. Enrollment in the Phase 1b expansion portion of the study will now commence and is designed to evaluate two dosing cohorts of 12 patients each at an oral dose of 240mg or 320 mg once daily. Three patients already enrolled in the study have been dosed at the 320 mg dose level.

Key Points: 
  • The study’s Safety Review Committee (SRC) completed its evaluation and determined that doses up to and including 320 mg once daily are tolerable with no dose limiting toxicities.
  • Enrollment in the Phase 1b expansion portion of the study will now commence and is designed to evaluate two dosing cohorts of 12 patients each at an oral dose of 240mg or 320 mg once daily.
  • Three patients already enrolled in the study have been dosed at the 320 mg dose level.
  • “We are very pleased to have completed the dose escalation portion of our Phase 1 study of IMM-1-104 ahead of our original timeline,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering.

Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

Retrieved on: 
星期日, 六月 4, 2023
Roswell Park Comprehensive Cancer Center, American Society of Clinical Oncology, The James Cancer Hospital, Doctor of Philosophy, Oncogene, Incidence, DO, Metabolism, Patient, The Cancer Genome Atlas, Risk, Informatics, Colorectal cancer, Body mass index, H. Lee Moffitt Cancer Center & Research Institute, TCGA, PSA, Prostate cancer, MYC, University, National Cancer Institute, AYA, Research, MS, Cancer, Diagnosis, Growth, BMI, Smoking, PD-L1, Metastasis, Behavior, NRAS, University of Oklahoma Health Sciences Center, Lipid, Cell, Dicarboxylic acid, Ohio State University, CRC, Health informatics, ASCO, Kynurenine, CDT, Gene, Society, Pharmaceutical industry, Birth control, Medical imaging, Upstate New York, MD, Roswell Park

That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.

Key Points: 
  • That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.
  • The team hopes the results of their study will help future studies zero in on new ways of treating colorectal cancer in younger patients.
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .